Background: Patients with HIV infection frequently experience disease or treatment-related myelosuppression leading to neutropenia. Neutropenia often leads to dose-reduction or discontinuation of important myelosuppressive therapy. Objective: To examine the efficacy and safety of filgrastim for reversing neutropenia and determine the effect of this on use of myelosuppressive medications. Design: Open-label, non-comparative, multicentre study in 200 HIV-positive patients with neutropenia [absolute neutrophil count (ANC) < 1.0 x 10(9)/l]. Filgrastim was started at 1 mu g/kg/day subcutaneously for 28 days. This initial treatment phase was followed by a maintenance phase, using 300 mu g on 1-7 days/week. In both phases the dose of filgrastim was adjusted to achieve an ANC of 2-5 x 10(9)/l. Results: Filgrastim reversed neutropenia in 98% of patients (ANC greater than or equal to 2 x 10(9)/l), with a median time to reversal of 2 days (range 1-16) and a median dose of 1 mu g/kg/day (range 0.5-10). Most patients (96%) achieved reversal of neutropenia with a filgrastim dose of less than or equal to 300 mu g/day (less than or equal to 1 vial/day). Normal ANCs were then maintained with a median of 1 mu g/kg/day (range 0.22-10.6) during the treatment phase and 3 x 300 pg vials/week (range 1-7) during the maintenance phase. Ganciclovir, zidovudine, co-trimoxazole and pyrimethamine were the drugs most frequently considered to be causing neutropenia, and 83% of patients received one or more of these in the study. Filgrastim allowed > 80% of patients to increase or maintain dose-levels of these four medications or add them to their therapy. The number of these four medications received per patient increased by > 20% during filgrastim therapy. Filgrastim was well tolerated. CD4, CD8 and total lymphocyte counts all increased slightly, and there was no difference in HIV-1 p24 antigen levels. Conclusion: Filgrastim rapidly reverses neutropenia and maintains normal ANC in patients with HIV infection. This allows greater use of myelosuppressive medications without the potentially life-threatening complications of neutropenia.

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection / P. Hermans, W. Rozenbaum, A. Jou, F. Castelli, J. Borleffs, S. Gray, N. Ward, A. Gori, A. Debona, C. Ferre, M. Lonca, J. Lang, A. Ammassari, N. Clumeck. - In: AIDS. - ISSN 0269-9370. - 10:14(1996), pp. 1627-1633.

Filgrastim to treat neutropenia and support myelosuppressive medication dosing in HIV infection

Gori A;
1996

Abstract

Background: Patients with HIV infection frequently experience disease or treatment-related myelosuppression leading to neutropenia. Neutropenia often leads to dose-reduction or discontinuation of important myelosuppressive therapy. Objective: To examine the efficacy and safety of filgrastim for reversing neutropenia and determine the effect of this on use of myelosuppressive medications. Design: Open-label, non-comparative, multicentre study in 200 HIV-positive patients with neutropenia [absolute neutrophil count (ANC) < 1.0 x 10(9)/l]. Filgrastim was started at 1 mu g/kg/day subcutaneously for 28 days. This initial treatment phase was followed by a maintenance phase, using 300 mu g on 1-7 days/week. In both phases the dose of filgrastim was adjusted to achieve an ANC of 2-5 x 10(9)/l. Results: Filgrastim reversed neutropenia in 98% of patients (ANC greater than or equal to 2 x 10(9)/l), with a median time to reversal of 2 days (range 1-16) and a median dose of 1 mu g/kg/day (range 0.5-10). Most patients (96%) achieved reversal of neutropenia with a filgrastim dose of less than or equal to 300 mu g/day (less than or equal to 1 vial/day). Normal ANCs were then maintained with a median of 1 mu g/kg/day (range 0.22-10.6) during the treatment phase and 3 x 300 pg vials/week (range 1-7) during the maintenance phase. Ganciclovir, zidovudine, co-trimoxazole and pyrimethamine were the drugs most frequently considered to be causing neutropenia, and 83% of patients received one or more of these in the study. Filgrastim allowed > 80% of patients to increase or maintain dose-levels of these four medications or add them to their therapy. The number of these four medications received per patient increased by > 20% during filgrastim therapy. Filgrastim was well tolerated. CD4, CD8 and total lymphocyte counts all increased slightly, and there was no difference in HIV-1 p24 antigen levels. Conclusion: Filgrastim rapidly reverses neutropenia and maintains normal ANC in patients with HIV infection. This allows greater use of myelosuppressive medications without the potentially life-threatening complications of neutropenia.
granulocyte-colony stimulating factor; filgrastim; treatment of neutropenia; myelosuppressive medication; HIV infection; AIDS
Settore MED/17 - Malattie Infettive
AIDS
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/629291
Citazioni
  • ???jsp.display-item.citation.pmc??? 6
  • Scopus 48
  • ???jsp.display-item.citation.isi??? 33
social impact